At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
UNCY Unicycive Therapeutics, Inc.
Not Yet Opened 10-13 16:00:00 EDT
3.73
-0.32
-7.90%
盘后3.77
+0.04+1.07%
19:57 EDT
High4.02Low3.67Vol1.84M
Open3.99D1 Closing4.05Amplitude8.64%
Mkt Cap103.90MTradable Cap101.55MTotal Shares27.86M
T/O6.97MT/O Rate6.76%Tradable Shares27.23M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Unicycive Therapeutics Appoints Meredith Manning to Board, Names Her Nominating Committee Chair
Reuters  ·  10-01
Unicycive Therapeutics Appoints Meredith Manning to Board, Names Her Nominating Committee Chair
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
THOMSON REUTERS  ·  10-01
Unicycive Therapeutics Appoints Meredith Manning to Board of Directors
Unicycive Therapeutics Price Target Cut to $13.00/Share from $15.00 by HC Wainwright & Co.
Dow Jones  ·  09-29
Unicycive Therapeutics Price Target Cut to $13.00/Share from $15.00 by HC Wainwright & Co.
Unicycive Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $13 from $15
THOMSON REUTERS  ·  09-29
Unicycive Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $13 from $15
Unicycive Therapeutics announces resubmission of NDA for OLC
TIPRANKS  ·  09-29
Unicycive Therapeutics announces resubmission of NDA for OLC
Unicycive Resubmits FDA NDA for Oxylanthanum Carbonate Phosphate Binder
Reuters  ·  09-29
Unicycive Resubmits FDA NDA for Oxylanthanum Carbonate Phosphate Binder
Unicycive Therapeutics - FDA Acceptance of Nda Expected Within 30 Days; New Pdufa Date in 6 Months
THOMSON REUTERS  ·  09-29
Unicycive Therapeutics - FDA Acceptance of Nda Expected Within 30 Days; New Pdufa Date in 6 Months
Unicycive Therapeutics - Nda Resubmission Includes Cmc Data from New Manufacturing Vendor
THOMSON REUTERS  ·  09-29
Unicycive Therapeutics - Nda Resubmission Includes Cmc Data from New Manufacturing Vendor
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
THOMSON REUTERS  ·  09-29
Unicycive Therapeutics Announces Resubmission of New Drug Application for Oxylanthanum Carbonate
Unicycive Therapeutics - FDA Inspection of Original Manufacturing Vendor Assigned but not Completed as of Sept 29, 2026
THOMSON REUTERS  ·  09-29
Unicycive Therapeutics - FDA Inspection of Original Manufacturing Vendor Assigned but not Completed as of Sept 29, 2026
Unicycive Therapeutics - Lawsuit Alleges Violations Related to Oxylanthanum Carbonate Phosphate Binder Statements - SEC Filing
THOMSON REUTERS  ·  09-29
Unicycive Therapeutics - Lawsuit Alleges Violations Related to Oxylanthanum Carbonate Phosphate Binder Statements - SEC Filing
Unicycive Therapeutics - Securities Class Action Lawsuit Filed Against Unicycive Therapeutics and Certain Officers on Sept 3, 2026 - SEC Filing
THOMSON REUTERS  ·  09-29
Unicycive Therapeutics - Securities Class Action Lawsuit Filed Against Unicycive Therapeutics and Certain Officers on Sept 3, 2026 - SEC Filing
Unicycive Therapeutics Faces Securities Class Action Tied to Oxylanthanum Phosphate Binder NDA Statements
Reuters  ·  09-29
Unicycive Therapeutics Faces Securities Class Action Tied to Oxylanthanum Phosphate Binder NDA Statements
Unicycive Therapeutics (UNCY) Gets a Buy from H.C. Wainwright
TIPRANKS  ·  09-22
Unicycive Therapeutics (UNCY) Gets a Buy from H.C. Wainwright
Unicycive Therapeutics Faces Securities Lawsuit After 39% Stock Plunge Over Repeat FDA Manufacturing Setback
TIPRANKS  ·  09-14
Unicycive Therapeutics Faces Securities Lawsuit After 39% Stock Plunge Over Repeat FDA Manufacturing Setback
Unicycive Therapeutics Outlines Oxylanthanum Carbonate Program for Hyperphosphatemia in Dialysis Patients
Reuters  ·  09-10
Unicycive Therapeutics Outlines Oxylanthanum Carbonate Program for Hyperphosphatemia in Dialysis Patients
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
GlobeNewswire  ·  09-01
Unicycive Therapeutics to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Unicycive Therapeutics price target raised to $15 from $13 at Benchmark
TIPRANKS  ·  08-20
Unicycive Therapeutics price target raised to $15 from $13 at Benchmark
U.S. Research Roundup-Amgen, Analog Devices, Moderna
Reuters  ·  08-20
U.S. Research Roundup-Amgen, Analog Devices, Moderna
Unicycive Therapeutics price target lowered to $20 from $22 at B. Riley
TIPRANKS  ·  08-17
Unicycive Therapeutics price target lowered to $20 from $22 at B. Riley

Introduction

Company Name.
Unicycive Therapeutics, Inc.
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.
Issue price:
--